Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped up prior to trading on Tuesday. The stock had previously closed at $34.5965, but opened at $36.80. Zealand Pharma A/S shares last traded at $36.75, with a volume of 600 shares traded.

Wall Street Analysts Forecast Growth

ZLDPF has been the subject of a number of research analyst reports. Barclays downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Jefferies Financial Group lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a market cap of $2.63 billion, a PE ratio of 6.09 and a beta of 0.99. The business’s 50 day moving average price is $39.26 and its 200-day moving average price is $47.12. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.